Analysis of the Effectiveness of the New Coronavirus Vaccines

This article analyzes the effectiveness of different types of COVID-19 vaccines. Live attenuated vaccines can significantly reduce viral load and alleviate pathological damage by introducing weakened pathogens into the human body, showing potential for single-dose vaccination and nasal administration, such as the COVI-VAC vaccine in preclinical studies. mRNA vaccines have demonstrated the ability to respond quickly to sudden outbreaks with their rapid R&D and production capabilities, which can be reflected in the efficient response and protection of infected people in the Hungarian study. Inactivated vaccines inactivate pathogens chemically/physically, and are characterized by high safety and convenient storage and transportation (2-8 C), which means they are suitable for areas with limited resources. This is reflected in studies in Chile and Pakistan, where their protection against severe illness, hospitalization, and death is over 86%. Recombinant protein vaccines express purified antigen proteins through genetic engineering. Taking Novavax as an example, it showed 89.7% protection efficacy in trials involving the elderly and people with underlying diseases, which reflects its applicability to special populations. Each type of vaccine has its own advantages in terms of technical paths, immune mechanisms and applicable scenarios, and together provide multiple options for epidemic prevention and control.